ASTRAZENECA, Pharmacyclics Inc. and Janssen Research & Development LLC entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Imbruvica (ibrutinib).
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
